Humana Dental Ranks Highest in Customer Satisfaction TROY, Mich.–(BUSINESS WIRE)–As dental practices continue to consolidate after two years of pandemic uncertainty, patient visits seem to be leaving a cavity of satisfaction. Overall satisfaction is down 15 points (on a 1,000-point scale) from a year ago, according to the J.D. Power 2022 U.S. Dental Plan Satisfaction … [Read more…]
Appoints Tuija Keinonen as Chair HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces it has completed the first close of its financing round raising $10.7 million (€10 million). The round was led by Lifeline Ventures and was joined by Tesi (Finnish Industry Investment Ltd). The funding will be used to advance … [Read more…]
ARLINGTON, Va. & MILAN, Italy–(BUSINESS WIRE)–The Digital Therapeutics Alliance (DTA) and Healthware Group today announced a partnership to form a coalition convening thought leaders, policymakers, and professional and trade associations from across the European region to discuss and develop harmonised pathways for the recognition and scalability of digital therapeutics (DTx) at the local, national, and … [Read more…]
Study shows that DecisionDx®-Melanoma results can provide patients with knowledge and understanding regarding their prognosis and inform melanoma treatment decisions FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a poster presentation on DecisionDx®-Melanoma at the recent 2022 Fall Clinical Dermatology Conference for … [Read more…]
Influx of capital will fuel WiL Ventures III fund, WiL Strategic Partners funds and Corporate Venture Capital funds; WiL’s capital commitments now exceed $1.9 billion WiL’s mission: bridge the innovation gap between Japan, the US and the rest of the world WiL’s investment thesis: provide growth investment capital for innovators across the spectrum of digital … [Read more…]
– No cerebral vascular anomaly before and after treatment observed – Successful completion of the FIM II clinical study prior to the pivotal study, that will pave the way for CE marking PARIS–(BUSINESS WIRE)–Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “General Anxiety Disorder Therapeutics Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type” report has been added to ResearchAndMarkets.com’s offering. This report describes the global market size of General Anxiety Disorder Therapeutics from 2017 to 2021 and its CAGR from 2017 to 2021, and also forecasts … [Read more…]
MILAN–(BUSINESS WIRE)–#IVASC–I-VASC, the Italy based start-up company which has developed and CE Marked its innovative percutaneous VELEX™ system to treat CVI, a condition that includes varicose veins disease, announces today that VELEX™ has entered clinical use, with the first two cases performed last week in Milan at the Policlinico San Donato center, the renowned institution … [Read more…]
SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that its partner, I-Mab (Nasdaq: IMAB), recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, … [Read more…]
Investment co-led by Jonathan Milner and Cambridge Enterprise US-based R42 Group, ACF Investors, o2h Ventures, Syndicate Room and the Cambridge Angels investing Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours CAMBRIDGE, England–(BUSINESS WIRE)–Spirea Limited, a Cambridge company created to advance a new generation of … [Read more…]
